title: Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole.
abstract: Twenty-four patients suffering from single or multiple lesions of cutaneous leishmaniasis were included in this study. Most of the lesions were on the extremities. The patients were randomly divided into two groups. Most of the patients in the first group who were given oral itraconazole for a period of 6-8 weeks showed excellent clinical response. On the other hand, only one patient in the second control group who was given placebo showed good clinical improvement. Systemically administered itraconazole may prove to be a valuable modality for the treatment of cutaneous leishmaniasis.
authors.affiliation: Department of Dermatology, Al-Sabah Hospital, Safat, Kuwait.
authors.forename: A S
authors.initials: AS
authors.lastname: al-Fouzan
authors.forename: Q A
authors.initials: QA
authors.lastname: al Saleh
authors.forename: N M
authors.initials: NM
authors.lastname: Najem
authors.forename: A I
authors.initials: AI
authors.lastname: Rostom
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D002648:Child; D005260:Female; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007730:Kuwait; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos
chemical_list: D000935:Antifungal Agents; D002214:Capsules; D010919:Placebos; D017964:Itraconazole; D007654:Ketoconazole